Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
暂无分享,去创建一个
Anurag K. Singh | P. Iyengar | H. Choy | R. Timmerman | A. Bezjak | J. Bradley | L. Gaspar | A. Sun | R. Mcgarry | R. Paulus | W. Straube | G. Videtic | J. Urbanic | W. F. Ryan | Y. Garces | A. Pu | J. Pantarotto | M. Daly | I. Grills | D. Normolle | P. Sperduto
[1] C. Simone,et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. , 2017, Practical radiation oncology.
[2] Y. Ung,et al. Guideline for radiotherapy with curative intent in patients with early-stage medically inoperable non-small-cell lung cancer. , 2017, Current oncology.
[3] I. Lax,et al. OA24.05 The Nordic HILUS-Trial - First Report of a Phase II Trial of SBRT of Centrally Located Lung Tumors , 2017 .
[4] S. Senan,et al. Outcomes of Hypofractionated High‐Dose Radiotherapy in Poor‐Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] A. Ward,et al. Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply? , 2016, The British journal of radiology.
[6] E. Yorke,et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. , 2016, Practical radiation oncology.
[7] S. Senan,et al. Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[8] A. Chaudhuri,et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. , 2015, Lung cancer.
[9] Roy H Decker,et al. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] J. Robertson,et al. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis. , 2015, International journal of radiation oncology, biology, physics.
[11] E. Yorke,et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. , 2014, International journal of radiation oncology, biology, physics.
[12] Joe Y. Chang,et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". , 2014, International journal of radiation oncology, biology, physics.
[13] Suresh Senan,et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[14] Jose Belderbos,et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Andrea Bezjak,et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.
[16] Lech Papiez,et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. , 2009, International journal of radiation oncology, biology, physics.
[17] Lech Papiez,et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Daniel Normolle,et al. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.